Preparing your results

Our searching services are busy right now. Your search will reload in five seconds.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

C/EBPalpha arrests cell proliferation through direct inhibition of Cdk2 and Cdk4.

Molecular cell | Oct 30, 2001

http://www.ncbi.nlm.nih.gov/pubmed/11684017

The transcription factor CCAAT/enhancer binding protein alpha (C/EBPalpha) is a strong inhibitor of cell proliferation. We found that C/EBPalpha directly interacts with cdk2 and cdk4 and arrests cell proliferation by inhibiting these kinases. We mapped a short growth inhibitory region of C/EBPalpha between amino acids 175 and 187. This portion of C/EBPalpha is responsible for direct inhibition of cyclin-dependent kinases and causes growth arrest in cultured cells. C/EBPalpha inhibits cdk2 activity by blocking the association of cdk2 with cyclins. Importantly, the activities of cdk4 and cdk2 are increased in C/EBPalpha knockout livers, leading to increased proliferation. Our data demonstrate that the liver-specific transcription factor C/EBPalpha brings about growth arrest through direct inhibition of cdk2 and cdk4.

Pubmed ID: 11684017 RIS Download

Mesh terms: Amino Acid Sequence | Animals | CCAAT-Enhancer-Binding Protein-alpha | CDC2-CDC28 Kinases | Cell Division | Cell Fractionation | Cell Line | Cyclin-Dependent Kinase 2 | Cyclin-Dependent Kinase 4 | Cyclin-Dependent Kinases | Enzyme Inhibitors | Genes, Reporter | Liver | Mice | Mice, Knockout | Molecular Sequence Data | Nuclear Proteins | Protein Structure, Secondary | Protein-Serine-Threonine Kinases | Proto-Oncogene Proteins | Rats | Recombinant Fusion Proteins

Research resources used in this publication

None found

Research tools detected in this publication

None found

Data used in this publication

None found

Associated grants

  • Agency: NIA NIH HHS, Id: AG 00756
  • Agency: NIGMS NIH HHS, Id: GM 55188

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.